lixisenatide Adlyxin
Selected indexed studies
- Trial of Lixisenatide in Early Parkinson's Disease. (N Engl J Med, 2024) [PMID:38598572]
- GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. (Mol Metab, 2021) [PMID:33068776]
- Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. (Int J Mol Sci, 2023) [PMID:37445623]
_Worker-drafted node — pending editorial review._
Connections
lixisenatide Adlyxin is a side effect of
Sources
- Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. (2023) pubmed
- Trial of Lixisenatide in Early Parkinson's Disease. (2024) pubmed
- Lixisenatide. (2012) pubmed
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. (2015) pubmed
- Lixisenatide. (2017) pubmed
- GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. (2021) pubmed
- GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease. (2024) pubmed
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. (2012) pubmed
- Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. (2024) pubmed
- Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making? (2024) pubmed